S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
Log in

Incyte News Headlines (NASDAQ:INCY)

$78.60
+0.84 (+1.08 %)
(As of 10/21/2019 04:00 PM ET)
Today's Range
$77.01
Now: $78.60
$78.69
50-Day Range
$72.77
MA: $77.18
$81.82
52-Week Range
$57.00
Now: $78.60
$89.30
Volume864,118 shs
Average Volume1.30 million shs
Market Capitalization$16.90 billion
P/E Ratio95.85
Dividend YieldN/A
Beta1.05

Headlines

Incyte (NASDAQ INCY) News Headlines

Source:
DateHeadline
Zacks: Analysts Expect Incyte Co. (NASDAQ:INCY) Will Post Earnings of $0.65 Per ShareZacks: Analysts Expect Incyte Co. (NASDAQ:INCY) Will Post Earnings of $0.65 Per Share
www.americanbankingnews.com - October 21 at 3:18 AM
Innovent Biologics Announces Positive Updated Result from the Incyte-sponsored Phase II Trial of Pemigatinib in Patients with Previously Treated, Advanced CholangiocarcinomaInnovent Biologics Announces Positive Updated Result from the Incyte-sponsored Phase II Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma
www.prnewswire.com - October 20 at 8:30 PM
Innovent Biologics Announces Positive Updated Result from the Incyte-sponsored Phase II Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma - PRNewswireInnovent Biologics Announces Positive Updated Result from the Incyte-sponsored Phase II Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma - PRNewswire
www.prnewswire.com - October 20 at 8:17 PM
Why the Earnings Surprise Streak Could Continue for Incyte (INCY) - Yahoo FinanceWhy the Earnings Surprise Streak Could Continue for Incyte (INCY) - Yahoo Finance
finance.yahoo.com - October 18 at 12:50 PM
Why the Earnings Surprise Streak Could Continue for Incyte (INCY)Why the Earnings Surprise Streak Could Continue for Incyte (INCY)
finance.yahoo.com - October 18 at 12:50 PM
Incyte Co. Forecasted to Earn Q3 2019 Earnings of $0.42 Per Share (NASDAQ:INCY)Incyte Co. Forecasted to Earn Q3 2019 Earnings of $0.42 Per Share (NASDAQ:INCY)
www.americanbankingnews.com - October 18 at 6:41 AM
Novartis' Jakavi Meets Primary Goal in Phase III for GVHDNovartis' Jakavi Meets Primary Goal in Phase III for GVHD
finance.yahoo.com - October 17 at 1:38 PM
Incyte (INCY) Reports REACH2 Pivotal Trial of Ruxolitinib (Jakafi) Meets Primary Endpoint - StreetInsider.comIncyte (INCY) Reports REACH2 Pivotal Trial of Ruxolitinib (Jakafi) Meets Primary Endpoint - StreetInsider.com
www.streetinsider.com - October 16 at 7:48 AM
Incyte rerpots positive results in late-stage trial of treatment for GVHD - MarketWatchIncyte rerpots positive results in late-stage trial of treatment for GVHD - MarketWatch
www.marketwatch.com - October 16 at 7:48 AM
Incyte Announces that the REACH2 Pivotal Trial of Ruxolitinib (Jakafi®) Meets Primary Endpoint in Patients with Steroid-Refractory Acute Graft-Versus-Host DiseaseIncyte Announces that the REACH2 Pivotal Trial of Ruxolitinib (Jakafi®) Meets Primary Endpoint in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease
finance.yahoo.com - October 16 at 7:48 AM
Incyte rerpots positive results in late-stage trial of treatment for GVHDIncyte rerpots positive results in late-stage trial of treatment for GVHD
finance.yahoo.com - October 16 at 7:48 AM
Were Hedge Funds Right About Dumping Incyte Corporation (INCY)? - Yahoo FinanceWere Hedge Funds Right About Dumping Incyte Corporation (INCY)? - Yahoo Finance
finance.yahoo.com - October 15 at 7:03 PM
Were Hedge Funds Right About Dumping Incyte Corporation (INCY)?Were Hedge Funds Right About Dumping Incyte Corporation (INCY)?
finance.yahoo.com - October 15 at 7:03 PM
Incytes ruxolitinib cream shows sustained benefit in mid-stage vitiligo study - Seeking AlphaIncyte's ruxolitinib cream shows sustained benefit in mid-stage vitiligo study - Seeking Alpha
seekingalpha.com - October 15 at 4:00 AM
Mizuho Securities Reiterates Buy Rating on Incyte (INCY) - StreetInsider.comMizuho Securities Reiterates Buy Rating on Incyte (INCY) - StreetInsider.com
www.streetinsider.com - October 14 at 2:10 PM
Is Incyte Corporations (NASDAQ:INCY) CEO Pay Justified? - Yahoo FinanceIs Incyte Corporation's (NASDAQ:INCY) CEO Pay Justified? - Yahoo Finance
finance.yahoo.com - October 14 at 2:10 PM
Incyte (INCY) Reports Positive 52-Wk Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo - StreetInsider.comIncyte (INCY) Reports Positive 52-Wk Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo - StreetInsider.com
www.streetinsider.com - October 14 at 8:58 AM
Incyte Co. (NASDAQ:INCY) Short Interest UpdateIncyte Co. (NASDAQ:INCY) Short Interest Update
www.americanbankingnews.com - October 12 at 7:47 PM
Incyte Announces Positive 52-Week Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo - Business WireIncyte Announces Positive 52-Week Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo - Business Wire
www.businesswire.com - October 12 at 1:57 PM
Incyte Announces Positive 52-Week Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With VitiligoIncyte Announces Positive 52-Week Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo
www.businesswire.com - October 12 at 5:16 AM
bluebird Inks Genome Editing Research Deal With Novo Nordisk - Nasdaqbluebird Inks Genome Editing Research Deal With Novo Nordisk - Nasdaq
www.nasdaq.com - October 10 at 6:35 PM
bluebird Inks Genome Editing Research Deal With Novo Nordisk - Yahoo Financebluebird Inks Genome Editing Research Deal With Novo Nordisk - Yahoo Finance
finance.yahoo.com - October 10 at 1:34 PM
bluebird Inks Genome Editing Research Deal With Novo Nordiskbluebird Inks Genome Editing Research Deal With Novo Nordisk
finance.yahoo.com - October 10 at 1:34 PM
Incyte to Report Third Quarter Financial Results - Business WireIncyte to Report Third Quarter Financial Results - Business Wire
www.businesswire.com - October 10 at 8:34 AM
Incyte to Report Third Quarter Financial ResultsIncyte to Report Third Quarter Financial Results
finance.yahoo.com - October 10 at 8:33 AM
BriaCell Therapeutics Corp. to File Amendment to Management Information Circular - Yahoo FinanceBriaCell Therapeutics Corp. to File Amendment to Management Information Circular - Yahoo Finance
finance.yahoo.com - October 8 at 11:05 PM
Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology (EADV) CongressLilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress
finance.yahoo.com - October 8 at 8:01 AM
BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer - Yahoo FinanceBriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer - Yahoo Finance
finance.yahoo.com - October 7 at 1:44 PM
BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer - GlobeNewswireBriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer - GlobeNewswire
www.globenewswire.com - October 7 at 8:44 AM
3 Drug Stocks Poised for Gains After Cancer Conference - Investopedia3 Drug Stocks Poised for Gains After Cancer Conference - Investopedia
www.investopedia.com - October 4 at 3:39 PM
Incyte Sees Hammer Chart Pattern: Time to Buy? - Yahoo FinanceIncyte Sees Hammer Chart Pattern: Time to Buy? - Yahoo Finance
finance.yahoo.com - October 4 at 3:39 PM
Incyte Sees Hammer Chart Pattern: Time to Buy?Incyte Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - October 4 at 8:32 AM
Is Incyte (INCY) Stock Outpacing Its Medical Peers This Year? - Yahoo FinanceIs Incyte (INCY) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
finance.yahoo.com - October 3 at 5:32 PM
Bausch Files Lawsuit Against Novartis' Sandoz, Shares DownBausch Files Lawsuit Against Novartis' Sandoz, Shares Down
finance.yahoo.com - October 3 at 5:31 PM
Incyte (NASDAQ:INCY) Now Covered by Analysts at MizuhoIncyte (NASDAQ:INCY) Now Covered by Analysts at Mizuho
www.americanbankingnews.com - October 2 at 10:53 PM
Mizuho Securities Starts Incyte (INCY) at Buy - StreetInsider.comMizuho Securities Starts Incyte (INCY) at Buy - StreetInsider.com
www.streetinsider.com - October 2 at 8:50 PM
Incyte (NASDAQ:INCY) PT Set at $101.00 by GuggenheimIncyte (NASDAQ:INCY) PT Set at $101.00 by Guggenheim
www.americanbankingnews.com - September 30 at 8:20 PM
Incytes (INCY) Buy Rating Reiterated at CowenIncyte's (INCY) Buy Rating Reiterated at Cowen
www.americanbankingnews.com - September 30 at 7:20 PM
Incyte Corp.: Maybe The Next Netflix - Seeking AlphaIncyte Corp.: Maybe The Next Netflix - Seeking Alpha
seekingalpha.com - September 30 at 3:58 PM
Incyte (INCY) Presents At ESMO Congress 2019 - SlideshowIncyte (INCY) Presents At ESMO Congress 2019 - Slideshow
seekingalpha.com - September 30 at 1:18 PM
Incyte (NASDAQ:INCY) PT Raised to $110.00 at JMP SecuritiesIncyte (NASDAQ:INCY) PT Raised to $110.00 at JMP Securities
www.americanbankingnews.com - September 30 at 10:20 AM
The 3 Best Health-Care Stocks This Month. And the Worst - BarronsThe 3 Best Health-Care Stocks This Month. And the Worst - Barron's
www.barrons.com - September 30 at 8:11 AM
$540.90 Million in Sales Expected for Incyte Co. (NASDAQ:INCY) This Quarter$540.90 Million in Sales Expected for Incyte Co. (NASDAQ:INCY) This Quarter
www.americanbankingnews.com - September 30 at 2:59 AM
Incyte on go with U.S. application for pemigatinib in bile duct cancer in Q4Incyte on go with U.S. application for pemigatinib in bile duct cancer in Q4
seekingalpha.com - September 29 at 5:01 PM
Zacks: Brokerages Expect Incyte Co. (NASDAQ:INCY) to Announce $0.50 EPSZacks: Brokerages Expect Incyte Co. (NASDAQ:INCY) to Announce $0.50 EPS
www.americanbankingnews.com - September 28 at 12:21 PM
Incyte (INCY) Stock Up 16% YTD on Strong Jakafi Performance - Yahoo FinanceIncyte (INCY) Stock Up 16% YTD on Strong Jakafi Performance - Yahoo Finance
finance.yahoo.com - September 27 at 9:15 PM
Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma - StreetInsider.comIncyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma - StreetInsider.com
www.streetinsider.com - September 27 at 4:15 PM
Incyte (INCY) Reports Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients - StreetInsider.comIncyte (INCY) Reports Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients - StreetInsider.com
www.streetinsider.com - September 27 at 8:09 AM
Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma - Business WireIncyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma - Business Wire
www.businesswire.com - September 27 at 8:09 AM
Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced CholangiocarcinomaIncyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma
finance.yahoo.com - September 27 at 8:09 AM
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel